Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Cardiac and vascular toxicity of chemotherapies].
Ederhy S, Ancedy Y, Champiat S, Lopez-Trabada-Ataz D, Dulery R, Cohen A. Ederhy S, et al. Among authors: champiat s. Rev Prat. 2018 Mar;68(3):326-329. Rev Prat. 2018. PMID: 30869300 French.
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer.
Prenen H, Deva S, Keam B, Lindsay CR, Lugowska I, Yang JC, Longo F, de Miguel M, Ponz-Sarvise M, Ahn MJ, Gumus M, Champiat S, Italiano A, Salas S, Perets R, Arslan C, Cho BC, Evers S, Boetsch C, Marbach D, Dejardin D, Sleiman N, Ardeshir C, Richard M, Charo J, Kraxner A, Keshelava N, Teichgräber V, Moreno V. Prenen H, et al. Among authors: champiat s. Clin Cancer Res. 2024 Jul 15;30(14):2945-2953. doi: 10.1158/1078-0432.CCR-23-2677. Clin Cancer Res. 2024. PMID: 38709220 Clinical Trial.
Myocarditis with Immune Checkpoint Blockade.
Ederhy S, Voisin A-L, Champiat S. Ederhy S, et al. Among authors: champiat s. N Engl J Med. 2017 Jan 19;376(3):290-1. doi: 10.1056/NEJMc1615251. N Engl J Med. 2017. PMID: 28102662 No abstract available.
The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study.
Michot JM, Lappara A, Le Pavec J, Simonaggio A, Collins M, De Martin E, Danlos FX, Ammari S, Cauquil C, Ederhy S, Barreau E, Belkhir R, Berdelou A, Lazarovici J, Chanson P, Izzedine H, Seferian A, Le Pajolec C, Baldini C, Martin-Romano P, Mariette X, Robert C, Besse B, Hollebecque A, Varga A, Laghouati S, Mateus C, Voisin AL, Soria JC, Massard C, Marabelle A, Champiat S, Lambotte O. Michot JM, et al. Among authors: champiat s. Eur J Cancer. 2020 May;130:39-50. doi: 10.1016/j.ejca.2020.02.010. Epub 2020 Mar 12. Eur J Cancer. 2020. PMID: 32172197
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines.
Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, Farnault L, Charbonnier A, Mirabel M, Champiat S, Cohen-Solal A, Cohen A, Dolladille C, Thuny F. Alexandre J, et al. Among authors: champiat s. J Am Heart Assoc. 2020 Sep 15;9(18):e018403. doi: 10.1161/JAHA.120.018403. Epub 2020 Sep 5. J Am Heart Assoc. 2020. PMID: 32893704 Free PMC article.
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
Hajem S, Ederhy S, Champiat S, Troalen F, Nolin-Lapalme A, Berhoune M, Cauquil C, Martin-Romano P, Baldini C, Laparra A, Vuagnat P, Hollebecque A, Mateus C, Besse B, Naltet C, Robert C, Marabelle A, Massard C, Lambotte O, Michot JM. Hajem S, et al. Among authors: champiat s. Eur J Cancer. 2021 Nov;157:383-390. doi: 10.1016/j.ejca.2021.08.045. Epub 2021 Sep 24. Eur J Cancer. 2021. PMID: 34571335
126 results